DK3818078T3 - Fremgangsmåder til fremstilling af rekombinante proteiner - Google Patents
Fremgangsmåder til fremstilling af rekombinante proteiner Download PDFInfo
- Publication number
- DK3818078T3 DK3818078T3 DK19745845.8T DK19745845T DK3818078T3 DK 3818078 T3 DK3818078 T3 DK 3818078T3 DK 19745845 T DK19745845 T DK 19745845T DK 3818078 T3 DK3818078 T3 DK 3818078T3
- Authority
- DK
- Denmark
- Prior art keywords
- production
- methods
- recombinant proteins
- recombinant
- proteins
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862693606P | 2018-07-03 | 2018-07-03 | |
PCT/US2019/040298 WO2020010080A1 (en) | 2018-07-03 | 2019-07-02 | Methods of producing recombinant proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3818078T3 true DK3818078T3 (da) | 2024-05-21 |
Family
ID=67470657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19745845.8T DK3818078T3 (da) | 2018-07-03 | 2019-07-02 | Fremgangsmåder til fremstilling af rekombinante proteiner |
Country Status (23)
Country | Link |
---|---|
US (1) | US20210253996A1 (da) |
EP (2) | EP4368699A3 (da) |
JP (2) | JP7419273B2 (da) |
KR (1) | KR20210027427A (da) |
CN (1) | CN112839954A (da) |
AU (1) | AU2019299358A1 (da) |
BR (1) | BR112020025623A2 (da) |
CA (1) | CA3104684A1 (da) |
DK (1) | DK3818078T3 (da) |
EA (1) | EA202092904A1 (da) |
ES (1) | ES2976708T3 (da) |
FI (1) | FI3818078T3 (da) |
HR (1) | HRP20240584T1 (da) |
HU (1) | HUE066560T2 (da) |
IL (1) | IL279782A (da) |
LT (1) | LT3818078T (da) |
MX (1) | MX2020013633A (da) |
PL (1) | PL3818078T3 (da) |
PT (1) | PT3818078T (da) |
RS (1) | RS65472B1 (da) |
SG (1) | SG11202012582QA (da) |
SI (1) | SI3818078T1 (da) |
WO (1) | WO2020010080A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023242238A1 (en) * | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Cell culture processes |
EP4339274A1 (en) | 2022-09-13 | 2024-03-20 | Sartorius Stedim Biotech GmbH | Method for operating a bioprocess installation for production of a bioproduct |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP1260521B1 (en) | 1991-08-14 | 2007-11-21 | Genentech Inc. | Immunoglobulin variants for specific Fc epsilon receptors |
AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CA2176811C (en) | 1993-12-10 | 2008-01-29 | David Tai Wai Fei | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
JP3825798B2 (ja) | 1994-01-18 | 2006-09-27 | ジェネンテク,インコーポレイテッド | IgEアンタゴニストを用いる寄生虫感染症の治療法 |
EP0749488A1 (en) | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
IL125255A (en) | 1996-01-23 | 2002-02-10 | Genentech Inc | Anti-cd18 antibodies for treating stroke |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
IL130143A0 (en) | 1996-11-27 | 2000-06-01 | Genentech Inc | Humanized anti-CD11a antibodies |
DE69836729T2 (de) | 1997-04-07 | 2007-12-13 | Genentech, Inc., South San Francisco | Anti-vefg antibodies |
CA2287911C (en) | 1997-05-15 | 2014-05-06 | Genentech, Inc. | Apo-2 receptor |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
EP1226177B1 (en) | 1999-10-29 | 2008-07-09 | Genentech, Inc. | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
RU2518289C2 (ru) * | 2006-09-13 | 2014-06-10 | Эббви Инк, | Способ получения антитела или его фрагмента с подпиткой (варианты) |
PT2673296T (pt) * | 2011-02-07 | 2019-01-31 | Cerenis Therapeutics Holding Sa | Complexos de lipoproteínas e sua fabricação e utilização |
ES2788132T3 (es) * | 2011-07-01 | 2020-10-20 | Amgen Inc | Cultivo de células de mamífero |
WO2015186075A1 (en) * | 2014-06-03 | 2015-12-10 | Lupin Limited | Cell culture process for producing a protein |
WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2019
- 2019-07-02 AU AU2019299358A patent/AU2019299358A1/en active Pending
- 2019-07-02 CN CN201980044908.3A patent/CN112839954A/zh active Pending
- 2019-07-02 EA EA202092904A patent/EA202092904A1/ru unknown
- 2019-07-02 EP EP24153543.4A patent/EP4368699A3/en active Pending
- 2019-07-02 US US17/252,163 patent/US20210253996A1/en active Pending
- 2019-07-02 DK DK19745845.8T patent/DK3818078T3/da active
- 2019-07-02 PL PL19745845.8T patent/PL3818078T3/pl unknown
- 2019-07-02 WO PCT/US2019/040298 patent/WO2020010080A1/en active Application Filing
- 2019-07-02 HU HUE19745845A patent/HUE066560T2/hu unknown
- 2019-07-02 KR KR1020217003056A patent/KR20210027427A/ko unknown
- 2019-07-02 LT LTEPPCT/US2019/040298T patent/LT3818078T/lt unknown
- 2019-07-02 RS RS20240475A patent/RS65472B1/sr unknown
- 2019-07-02 JP JP2020573229A patent/JP7419273B2/ja active Active
- 2019-07-02 BR BR112020025623-4A patent/BR112020025623A2/pt unknown
- 2019-07-02 MX MX2020013633A patent/MX2020013633A/es unknown
- 2019-07-02 ES ES19745845T patent/ES2976708T3/es active Active
- 2019-07-02 CA CA3104684A patent/CA3104684A1/en active Pending
- 2019-07-02 EP EP19745845.8A patent/EP3818078B1/en active Active
- 2019-07-02 SG SG11202012582QA patent/SG11202012582QA/en unknown
- 2019-07-02 HR HRP20240584TT patent/HRP20240584T1/hr unknown
- 2019-07-02 SI SI201930722T patent/SI3818078T1/sl unknown
- 2019-07-02 PT PT197458458T patent/PT3818078T/pt unknown
- 2019-07-02 FI FIEP19745845.8T patent/FI3818078T3/fi active
-
2020
- 2020-12-25 IL IL279782A patent/IL279782A/en unknown
-
2024
- 2024-01-10 JP JP2024001657A patent/JP2024050590A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI3818078T1 (sl) | 2024-05-31 |
EP3818078A1 (en) | 2021-05-12 |
WO2020010080A1 (en) | 2020-01-09 |
IL279782A (en) | 2021-03-01 |
EP4368699A2 (en) | 2024-05-15 |
HUE066560T2 (hu) | 2024-08-28 |
AU2019299358A1 (en) | 2021-02-18 |
RS65472B1 (sr) | 2024-05-31 |
CN112839954A (zh) | 2021-05-25 |
KR20210027427A (ko) | 2021-03-10 |
LT3818078T (lt) | 2024-04-25 |
BR112020025623A2 (pt) | 2021-03-23 |
EP3818078B1 (en) | 2024-02-28 |
EA202092904A1 (ru) | 2021-04-22 |
CA3104684A1 (en) | 2020-01-09 |
SG11202012582QA (en) | 2021-01-28 |
JP2021529527A (ja) | 2021-11-04 |
PT3818078T (pt) | 2024-04-18 |
JP2024050590A (ja) | 2024-04-10 |
HRP20240584T1 (hr) | 2024-07-19 |
ES2976708T3 (es) | 2024-08-07 |
FI3818078T3 (fi) | 2024-05-14 |
PL3818078T3 (pl) | 2024-04-29 |
MX2020013633A (es) | 2021-03-25 |
JP7419273B2 (ja) | 2024-01-22 |
EP4368699A3 (en) | 2024-09-11 |
US20210253996A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53616A (fr) | Protéines bispécifiques modifiées | |
DK3292141T3 (da) | Fusionsproteiner | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3287523T3 (da) | Fremgangsmåde til sekretorisk fremstilling af protein | |
DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
MA53498A (fr) | Production de protéines recombinantes | |
DK3746466T3 (da) | Fremstilling af glucagonpeptider | |
DK3630977T3 (da) | Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer | |
DK3833662T3 (da) | Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2- | |
DK3199179T3 (da) | Formulering af rekombinant fusionsprotein | |
DK3218396T3 (da) | Fremgangsmåde til fremstilling af højaffinitets antistoffer | |
DK3460102T3 (da) | Fremgangsmåde til fremstilling af en elektrokatalysator | |
DK3737402T5 (da) | Modificeret protein | |
DK3728288T3 (da) | Fremgangsmåder til forbedret fjernelse af urenheder under protein a-kromatografi | |
DK3784047T3 (da) | Gærproteiner | |
DK3618845T3 (da) | Peptider til behandling af diabetes | |
DK3591122T3 (da) | Hurtigskifter | |
DK3833786T3 (da) | Rekombinant nucleinsyrekonstrukt | |
DK3405476T3 (da) | Fremgangsmåde til fremstilling af peptider med psWANG linker | |
DK3818078T3 (da) | Fremgangsmåder til fremstilling af rekombinante proteiner | |
DK3723791T3 (da) | Rekombinante igg-fc-multimere til behandling af neuromyelitis optica | |
DK3183359T3 (da) | Effektiv valg af rekombinante proteiner | |
DK3620452T3 (da) | Fremgangsmåde til fremstilling af lenvatinib | |
DK3544068T3 (da) | Fremgangsmåde til fremstilling af termoelektriske mikrokølere | |
DK3630793T3 (da) | Rekombinant protein |